Bevacizumab in Clinical Practice: Prescribing Appropriateness Relative to National Indications and Safety
Bonifazi et al.
The Oncologist 2012;17:117-124.
ABSTRACT
| FULL TEXT
The End of the Risk-Treatment Paradox?: A Rising Tide Lifts All Boats
McAlister
J Am Coll Cardiol 2011;58:1766-1767.
FULL TEXT
Enhancing Prescription Drug Innovation and Adoption
Alexander et al.
ANN INTERN MED 2011;154:833-837.
ABSTRACT
| FULL TEXT
A Hemorrhage of Off-Label Use
Avorn and Kesselheim
ANN INTERN MED 2011;154:566-567.
FULL TEXT
Off-label use of rituximab in a multipayer insurance system.
Van Allen et al.
J Oncol Pract 2011;7:76-79.
ABSTRACT
| FULL TEXT
Off-label prescribing in people with recurrent depressive disorder attending a community mental health service
Uzoechina et al.
The Psychiatrist 2011;35:84-89.
ABSTRACT
| FULL TEXT
Neuroethical issues in cognitive enhancement
Sahakian and Morein-Zamir
J Psychopharmacol 2011;25:197-204.
ABSTRACT
| FULL TEXT
Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0
Carmona et al.
Rheumatology (Oxford) 2011;50:85-92.
ABSTRACT
| FULL TEXT
Off-Label Use and Prescribing What Does It Mean for the Foot and Ankle Surgeon?
Hyer
Foot Ankle Spec 2010;3:303-306.
ABSTRACT
Comparative Effectiveness Research: From Clinical Information To Economic Incentives
Robinson
Health Aff (Millwood) 2010;29:1788-1795.
ABSTRACT
| FULL TEXT
Importance of Distinguishing Supported and Unsupported Off-label Drug Use
Walton et al.
Arch Intern Med 2010;170:657-658.
FULL TEXT
Reforming Off-Label Promotion to Enhance Orphan Disease Treatment
Liang and Mackey
Science 2010;327:273-274.
ABSTRACT
| FULL TEXT
Impact of FDA Black Box Advisory on Antipsychotic Medication Use
Dorsey et al.
Arch Intern Med 2010;170:96-103.
ABSTRACT
| FULL TEXT
Critical Review of the Determination Process by the Japanese Reviewing Authority in Approving the Additional Efficacy of Fludarabine Phosphate
Narimatsu et al.
JCO 2009;27:e236-e238.
FULL TEXT
Going Off-label Without Venturing Off-Course: Evidence and Ethical Off-label Prescribing
Largent et al.
Arch Intern Med 2009;169:1745-1747.
FULL TEXT
Pharmacists' role in facilitating evidence-based prescribing for unlabeled use of medications
Macaulay et al.
Am J Health Syst Pharm 2009;66:1735-1739.
FULL TEXT
Systematic Review: Reliability of Compendia Methods for Off-Label Oncology Indications
Abernethy et al.
ANN INTERN MED 2009;150:336-343.
ABSTRACT
| FULL TEXT
Controlling Off-Label Medication Use
Gillick
ANN INTERN MED 2009;150:344-347.
ABSTRACT
| FULL TEXT
Commentary: Risk/Benefit Ratio of Androgen Deprivation Treatment for Sex Offenders
Berlin
J Am Acad Psychiatry Law 2009;37:59-62.
ABSTRACT
| FULL TEXT
Current Status and Future Prospects of Clinical Psychology: Toward a Scientifically Principled Approach to Mental and Behavioral Health Care
Baker et al.
Psychological Science in the Public Interest 2008;9:67-103.
ABSTRACT
| FULL TEXT
Cardiac Resynchronization Therapy for Heart Failure: A Hammer in Search of Nails
McAlister
Circulation 2008;118:901-903.
FULL TEXT
FDA Guidance on Off-Label Promotion and the State of the Literature From Sponsors
Psaty and Ray
JAMA 2008;299:1949-1951.
FULL TEXT
Gabapentin: a multimodal perioperative drug?
Kong and Irwin
Br J Anaesth 2007;99:775-786.
ABSTRACT
| FULL TEXT
Indication creep: physician beware
Hebert and Stanbrook
CMAJ 2007;177:697-697.
FULL TEXT
L'expansion des indications : medecins, attention
Hebert and Stanbrook
CMAJ 2007;177:699-699.
FULL TEXT
What Cannot Be Said on Television About Health Care
Emanuel
JAMA 2007;297:2131-2133.
FULL TEXT
Positive Outcomes Through the Appropriate Use of Off-Label Prescribing
Bright
Arch Intern Med 2006;166:2554-2555.
FULL TEXT
Safeguarding Patient Welfare: Who's In Charge?
Henney
ANN INTERN MED 2006;145:305-307.
FULL TEXT